Últimas noticias sobre INLIF (NASDAQ:INLF) Bolsa

INLIF Ltd is a holding company and does business through its subsidiary. It is engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms also a provider of installation services and warranty services for manipulator arms, and accessories and raw materials for manipulator arms. The company portfolio includes injection molding machine-dedicated manipulator arms, including transverse single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms, and large bullhead multi-axis manipulator arms.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADTX

APTO

CSAI

DSGN

EFOI

EWCZ

GLYC

GRAB

HEES

INLF

LVWR

MGOL

MTRX

NESR

NTIC

RSLS

TNMG

Las acciones de GCL Global suben más del 100% en premercado tras su fusión. Descubre qué otras acciones están en movimiento hoy.

Acciones de GCL Global Holdings (GCL) se disparan un 107%; 20 acciones que se mueven en el premercado

INLIF Ltd

Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) reported quarterly earnings of $2.29 (Incl Discontinued Operations) per share which beat the analyst consensus estimate of $2.19 by 4.57 percent. This is a 10.2 percent decrease over earnings of $2.55 per share from the same period last year. The company reported quarterly sales of $8.24 billion (Incl Discontinued Operations) which met the analyst consensus estimate. This is a 4.65 percent decrease over sales of $8.64 billion the same period last year.

Earnings

Earnings Beats

DLTR

Dollar Tree Q4 Adj EPS (Incl Discontinued Operations) $2.29 Beats $2.19 Estimate, Sales $8.24B (Incl Discontinued Operations) Inline

ZLAB

Zai Lab Announced That New Data From Internally Developed, Next-generation Oncology Candidates Will Be Presented During Poster Sessions At The Upcoming American Association For Cancer Research (Aacr) Annual Meeting 2025 Taking Place April 25-30, 2025 In Chicago, Illinois

Per the Collaboration Agreement, Trident will join forces with Silkoo Dutyfree Limited, an e-commerce retailer and import-export trader, and Haitu Trade Co., Limited, an e-commerce entity specializing in beauty and cosmetics, to foster a synergistic partnership that drives business growth, enhances customer satisfaction, and promotes operational efficiency.
&nbsp;

TDTH

Trident Digital Tech Enters Strategic Collaboration Agreement With Two Partners In The E-commerce Sector

Earnings Misses

SAIL

SailPoint Q4 2024 GAAP EPS $(4.29) Misses $(0.11) Estimate, Sales $240.121M Beat $235.260M Estimate

TECH

Bio-techne Announced It Will Open A New Customer Experience Centre In Düsseldorf, Germany To Serve Customers Across The Europe, Middle East And Africa Region And Support The Company's Long-term Regional Growth Strategy

Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) reported quarterly losses of $(2.22) per share which missed the analyst consensus estimate of $(1.96) by 13.27 percent. This is a 45.32 percent increase over losses of $(4.06) per share from the same period last year. The company reported quarterly sales of $638.00 thousand which missed the analyst consensus estimate of $4.28 million by 85.08 percent. This is a 90.93 percent decrease over sales of $7.04 million the same period last year.

DTIL

Precision BioSciences Q4 2024 GAAP EPS $(2.22) Misses $(1.96) Estimate, Sales $638.00K May Not Be Comparable To $4.28M Estimate

PMNT

BWT Alpine Formula One Team And Luxury Skiwear And Lifestyle Brand Perfect Moment Ltd. Will Come Together To Reveal A Special-edition, Capsule Collection That Effortlessly Fuses Perfect Moment's Refined Ski Lifestyle With The Team's Cutting-edge, Racing Performance

Needham analyst Scott Berg reiterates UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) from Hold to Hold.

Reiteration

Analyst Ratings

PATH

Needham Reiterates Hold on UiPathto Hold

Stock Split

ACON

Aclarion Plans To Complete 1-For-27 Reverse Stock Split Of Its Common Stock, Effective Before Market Open On March 28, 2025

IONS

Ionis Pharmaceuticals Announced That It Has Entered Into A License Agreement Under Which Sobi Receives Exclusive Rights In Countries Outside The U.S., Canada And China To Commercialize Olezarsen As A Potential Treatment For Familial Chylomicronemia Syndrome And Severely Elevated Triglycerides

CODA

Coda Octopus Reported That Its Salt Lake City Based Defense Engineering Services Business, Coda Octopus Colmek, Recently Received Two Orders From The Us Government Totalling $1.3M

Needham analyst Scott Berg reiterates SPS Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>) with a Buy and maintains $210 price target.

Price Target

SPSC

Needham Reiterates Buy on SPS Commerce, Maintains $210 Price Target

Bridger Aerospace Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) shares are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading higher in premarket</a> on Wednesday.
On Tuesday, the company unveiled a strategic alliance with Positive Aviation, Inc. (PA), a French engineering firm, to serve as the exclusive North American launch customer for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44481112/bridger-aerospace-and-positive-aviation-announce-joint-partnership-for-the-development-of-water-sc" rel="noreferrer noopener">PA&#8217;s advanced </a><a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44481112/bridger-aerospace-and-positive-aviation-announce-joint-partnership-for-the-development-of-water-sc" rel="noreferrer noopener">FF72 </a><a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44481112/bridger-aerospace-and-positive-aviation-announce-joint-partnership-for-the-development-of-water-sc" rel="noreferrer noopener">firefighting aircraft.</a>
This new partnership was announced yesterday at the Aerial Fire Fighting Series: Europe Conference and Exhibition (AFFE25) in Bordeaux, France.
While the agreement is still subject to final negotiations, it is expected to strengthen Bridger&#8217;s fleet with amphibious aircraft specifically designed to tackle wildfires.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44475168/cognizant-partners-with-nvidia-to-enhance-enterprise-operations-with-neuro-ai-platform" rel="noreferrer noopener">Cognizant Boosts Stock Buyback, Partners With NVIDIA To Enhance Enterprise Operations With Neuro AI Platform</a>
&#8220;Bridger is the leading aerial firefighting company in North America and has long been recognized for its expertise in deploying, training, and providing aerial firefighting services to communities affected by wildfires,&#8221; said Chairman and Founder of PA, Laurent Schmitt.
&#8220;We are proud to partner with Bridger and are excited to develop this aircraft to meet the growing demand for cost-effective wildfire fighting solutions both in the U.S. and globally.&#8221;
FF72 Aircraft is a next-generation amphibious water-scooping model derived from the ATR 72-600, known for its reliability and efficiency.
Bridger&#8217;s expansion into this new technology will complement its existing fleet of CL-415 EAF Super Scoopers.
Under the partnership, Bridger Aerospace will take on sole responsibility for the marketing, sales, and support of the FF72 aircraft across North America.
As outlined in the Memorandum of Understanding (MOU), Bridger will oversee the aircraft&#8217;s modifications, certification processes, and the training of flight crews and mechanics, in addition to offering continuous in-service support.
The deal also presents the possibility of acquiring up to 20 FF72 units, with deliveries anticipated to start by 2029.
Price Action: BAER shares traded higher by 3.33% at $1.24 in premarket at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44457612/tilrays-hiball-energy-returns-to-whole-foods-market-details" target="_blank" rel="noreferrer noopener">Tilray&#8217;s Hi&#x2A;Ball Energy Returns To Whole Foods Market</a></li>
</ul>
Photo via Shutterstock.

Equities

Contracts

General

BAER

Bridger Aerospace Expands With Exclusive North American Deal For New Firefighting Aircraft

Vivani Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">overweight individuals</a>.
Semaglutide is the active ingredient in Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic and Wegovy, which are available for diabetes and weight loss.
In an ongoing study in healthy rats, a single administration of the semaglutide implant NPM-139 resulted in body weights nearly 20% lower than a sham implant control group throughout a 91-day treatment period.
NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44273204/exclusive-vivani-medical-to-spin-off-cortigent-neurostimulation-business-to-create-better-focus-on-individual-entities-and-shareholder-value" rel="noreferrer noopener">EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value</a>
Like NPM-119 and NPM-115, NPM-139 has demonstrated smooth, non-fluctuating in vivo release. The study demonstrated continuous and steady semaglutide exposure throughout the study period.
NPM-139 has previously demonstrated therapeutic semaglutide exposure levels in pharmacokinetic data over six months in healthy rats.
In-vitro chemical and physical stability measurements for durations exceeding one year indicate the potential for once-yearly administration of NPM-139.
The ongoing NPM-115 clinical study, LIBERATE-1, remains on track to produce top-line data by mid-2025.
Earlier this month,&nbsp;Vivani Medical announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44298354/exclusive-vivani-medical-announces-first-implant-in-early-stage-human-study-of-glp-1-implant-for-obesity" rel="noreferrer noopener">LIBERATE-1&nbsp;trial in Australia</a>.
Vivani&#8217;s lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight individuals.
Last year, Vivani Medical released preclinical data on weight loss effects for NPM-115.
In a study in high-fat diet-induced obese mice, NPM-115 generated weight loss of approximately 20% compared to a sham implant control after a <a target="_blank" href="https://www.benzinga.com/news/24/02/37361308/exclusive-vivani-medical-says-weight-lossdiabetes-implant-at-par-with-novo-nordisks-famed-injectable" rel="noreferrer noopener">28-day treatment duration</a>.
Price Action: VANI stock closed at $1.10 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/03/44473710/nokia-powers-post-luxembourgs-move-to-automated-broadband-network" target="_blank" rel="noreferrer noopener">Nokia Powers POST Luxembourg&#8217;s Move To Automated Broadband Network</a></li>
</ul>

Health Care

Market-Moving Exclusives

Exclusives

VANI

EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing

EXCLUSIVE: Vivani Medical Tells Benzinga 'NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing'

EXCLUSIVE: Vivani Medical Tells Benzinga 'NanoPortal technology successfully delivers semaglutide, the active ingredient in Ozempic/Wegovy, in a preclinical study with NPM-139'

EXCLUSIVE: Vivani Medical Tells Benzinga Co. Announces Preclinical Weight Loss Data For NPM-139 Semaglutide Implant, With Potential For Once-Year Dosing

Dollar Tree Reports Q4 Segment Sales Of $4.999B And Adj EPS Of $2.11

Needham analyst Tom Nikic maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Buy and lowers the price target from $475 to $430.

LULU

Needham Maintains Buy on Lululemon Athletica, Lowers Price Target to $430

Dollar Tree Posts Q4 Same-Store Sales Growth Of 2%

Press Releases

INLIF LIMITED Announces Closing of US$8 Million Initial Public Offering

Nuburu

ClearSign Technologies Corporation - Common Stock

ClearSign Technologies

Chicago Rivet & Machine

Desktop Metal

Eastern

Gencor Industries

Greenland Technologies Holding Corporation - Ordinary Shares

Greenland Technologies

Highway Holdings

Hurco Companies

INLIF

JE Cleantech Holdings Limited - Ordinary Shares

JE Cleantech Hldgs

Laser Photonics Corporation - Common Stock

Laser Photonics

Li Bang International Corporation Inc. - Ordinary Shares

Li Bang International

LiqTech International, Inc. - Common Stock

LiqTech Intl

Micropolis Holding Company Ordinary Shares

Micropolis Hldgs

Markforged Holding Corporation Common Stock

Markforged Holding

Nephros

Perma-Pipe International Holdings, Inc. - Common Stock

Perma-Pipe Inlt Hldgs

Rain Enhancement Technologies Holdco, Inc. - Class A Common Stock

Rain Enhancement

374Water

Taylor Devices

Techprecision

CleanCore Solutions Inc. Class B Common Stock

CleanCore Solutions

Comments

INLIF

Noticias

Últimas noticias sobre INLIF (NASDAQ:INLF) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL